If the US FDA approves it, aglatimagene immunotherapy may become the first new therapy for men with localized prostate cancer in the past 2 decades.

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of ...

Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has been dosed in its ...

"With a Phase 2a asset in HSV and an EBV program approaching clinical readiness, Innovative Molecules is uniquely positioned as a leading developer of next-generation therapies targeting herpesviruses ...

Last fall Alexa started seeing a man she met on a dating app. He asked her to get tested for sexually transmitted infections before they began having sex. The first thing she noticed on her screening ...